DSW Ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Mesenbiomesenbio.netinJan 2024
Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine.
BiotechHealthtechLongevity
Dr. David Kuntin(Chief Executive Officer)Prof. Paul Genever(Chief Scientific Officer)inAnita Adams(Finance Director)in
BoardDr. David Simpson(Chair)Jason Goldstein(Director)
Co-investorsInnovate UK
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.